Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes

被引：1

作者：

Tsai, Hsiu-Hui ^{[1
]}

Hsiao, Fu-Chih ^{[2
]}

Yu, Alice L. ^{[1
,3
]}

Juang, Jyuhn-Huarng ^{[4
,5
]}

Yu, John ^{[1
]}

Chu, Pao-Hsien ^{[1
,2
]}

机构：

[1] Chang Gung Univ, Chang Gung Mem Hosp, Inst Stem Cell & Translat Canc Res, Coll Med, Taoyuan, Taiwan

[2] Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol,Coll Med, Taoyuan, Taiwan

[3] Univ Calif San Diego, Dept Pediat, San Diego, CA USA

[4] Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Endocrinol & Metab,Coll Med, Taoyuan, Taiwan

[5] Chang Gung Univ, Chang Gung Mem Hosp, Ctr Tissue Engn, Coll Med, Taoyuan, Taiwan

来源：

STEM CELL REVIEWS AND REPORTS | 2025年 / 21卷 / 03期

关键词：

HiPSC; Cardiomyocyte; Diabetic cardiomyopathy; Empagliflozin; DIABETES-MELLITUS; INHIBITORS;

D O I：

10.1007/s12015-024-10839-8

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Human-induced pluripotent stem cell (hiPSC) technology has been applied in pathogenesis studies, drug screening, tissue engineering, and stem cell therapy, and patient-specific hiPSC-derived cardiomyocytes (hiPSC-CMs) have shown promise in disease modeling, including diabetic cardiomyopathy. High glucose (HG) treatment induces lipotoxicity in hiPSC-CMs, as evidenced by changes in cell size, beating rate, calcium handling, and lipid accumulation. Empagliflozin, an SGLT2 inhibitor, effectively mitigates the hypertrophic changes, abnormal calcium handling, and contractility impairment induced by HG. Glucose concentration influences SGLT2 expression in cardiomyocytes, highlighting its potential role in diabetic cardiomyopathy. These findings support the potential utility of hiPSC-CMs in studying diabetic cardiomyopathy and the efficacy of empagliflozin in ameliorating HG-induced cardiomyocyte dysfunction. Such research may advance developments in precision medicine and therapeutic interventions for patients with diabetic cardiomyopathy.

引用

页码：849 / 858

页数：10